Categories
All News

Obesity Pipeline: Industry Analysis, Key Pharma Companies, Clinical Trials and Drug Pipeline by DelveInsight

This post was originally published on this site

Categories
All News

Glioblastoma multiforme Market Insight, Epidemiology and Market Forecast -2030

Glioblastoma Multiforme Market

DelveInsight’sGlioblastoma Multiforme Market report delivers an in-depth understanding of the Glioblastoma Multiforme (GBM), historical and forecasted epidemiology as well as the Glioblastoma Multiforme (GBM) market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan.

The Glioblastoma Multiforme (GBM) market report provides current treatment practices, emerging drugs, and market share of the individual therapies, current and forecasted 7MM Glioblastoma Multiforme (GBM) market size from 2017 to 2030. The report also covers current Glioblastoma Multiforme (GBM) treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Glioblastoma Multiforme (GBM) Disease Understanding and Treatment Algorithm

Glioblastoma Multiforme (GBM) Overview

Glioblastoma (GBM) is the most frequently occurring type of primary tumors of the central nervous system (CNS) mostly in adults, and its poor prognosis has not been significantly improved despite the fact that the innovative diagnostic strategies and new therapies have been developed. Somatic evolution promotes the progression of cancer in which the genome of the cancer cell is being deviated from that of the healthy cell due the accumulation of mutations. There is a remarkable development in GBM because it occurs via a complex network of various different molecular and genetic aberrations, which leads to significant changes in major signaling pathways. GBMs, as they extensively disperse throughout the parenchyma, making maximal surgical resection unattainable and having high level of vascularization, are lethal in nature.

Glioblastoma Multiforme (GBM) Market Outlook

Glioblastoma is a malignant (cancerous) brain tumor that develops from a specific type of brain cell called an astrocyte. These cells help support and nourish neurons (nerve cells of the brain) and form scar tissue that helps repair brain damage in response to injury. Glioblastomas are often very aggressive and grow into surrounding brain tissue. Unfortunately, there is no cure for glioblastoma.

Glioblastoma treatment is quite challenging as some cells may respond well to certain therapies, while others may not be affected at all. Because of this, the treatment plan for glioblastoma may combine several approaches. The treatment often comprises a combination of several therapies, including surgery, chemotherapy, radiation, or stereotactic radiosurgery followed by the additional/adjuvant treatments, such as chemotherapy or radiation therapy, after surgery. Treatment is palliative and may include surgery, radiation therapy and/or chemotherapy. The best treatment options for each person depending on many factors like the size and location of the tumor; the extent to which the tumor has grown into the surrounding normal brain tissues; and the affected person’s age and overall health.

In April 2005, the FDA approved a new indication for Temodar capsules (temozolomide) for concurrent use with radiotherapy for the treatment of adults with newly diagnosed GBM and as maintenance therapy after radiotherapy. Inaddition, in December 2017, the FDA granted full approval of bevacizumab (Avastin) for the treatment of adults with recurrent glioblastoma that has progressed following prior therapy. In case of European and Japanese market, only Temodar has been approved by the EMA and MHLW respectively, for the treatment of patients with GBM.

Glioblastoma Multiforme pipeline is robust and possesses multiple potential drugs in late and mid-stage developments, which is yet to be launched. The pipeline involves drugs with a varied mechanism of action along with different routes of administration, ranging from oral, intravenous, intratumoral, subcutaneous, etc. It is interesting to note that the emerging market of GBM includes budding gene therapy, i.e., Ofranergene obadenovec (VB-111) by VBL Therapeutics, followed by four vaccine/immunotherapy candidates such as VBI-1901, AV-GBM-1 and ITI-1000 (pp65 DC Vaccine), Tasadenoturev (DNX-2401) by VBI Vaccines, Aivita Biomedical, Immunomic Therapeutics, and DNAtrix, respectively.

The potential candidates with promising results in late- or phase III stage of clinical development include Ofranergene obadenovec (VB-111; VBL Therapeutics), Trans Sodium Crocetinate (Diffusion Pharmaceuticals), and Regorafenib (Bayer).

Key Findings

This section includes a glimpse of the Glioblastoma Multiforme (GBM) 7MM market.

  • The market size of GBM in the seven major markets was estimated to be USD 1,005 Million in 2017.
  • The United States accounts for the largest market size of GBM throughout the study period of 2017–2030, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan, which was estimated to be USD 629 Million in 2017.
  • Among the EU5 countries, Germany had the highest market size with USD 73 Million in 2017, while Spain had the lowest market size with USD 35 Million.
  • Japan accounted for the second highest market size in the 7 MM during the forecast period of 2020–2030, which was estimated to be USD 82 Million in 2017.

Request for sample pages @ Glioblastoma Multiforme (GBM) market report

Table of contents

1. Key Insights

2. Glioblastoma Multiforme Market Overview at a Glance

2.1. Market Share (%) Distribution of GBM in 2017

2.2. Market Share (%) Distribution of GBM in 2030

3. Executive Summary of Glioblastoma Multiforme (GBM)

4. Disease Background and Overview: Glioblastoma Multiforme (GBM)

4.1. Introduction

4.2. Classification of Glioblastoma Multiforme

4.3. Glioblastoma Types

4.3.1. Astrocytomas

4.3.2. Ependymomas

4.3.3. Oligodendrogliomas

4.3.4. Mixed gliomas

4.3.5. Optic pathway gliomas

4.4. Symptoms

4.5. Pathophysiology

4.5.1. Macroscopic and Histological Features of GBM

4.5.2. Genetic and Molecular Pathogenesis

4.6. Inheritance of Glioblastoma Multiforme

4.6.1. Genetic Variations of Glioblastoma Multiforme

4.7. Molecular Classification

4.7.1. Specific Molecular Biomarkers

4.8. Diagnosis of Glioblastoma Multiforme

4.8.1. Neurological Exams

4.8.2. Angiograms

4.8.3. Magnetic resonance imaging (MRI) and computerized Tomography (CT)

4.8.4. Perfusion MRI

4.8.5. MR spectroscopy

4.8.6. Histological Diagnosis

4.8.7. Surgical Biopsy

4.9. Glioblastoma in Nut Shell

5. Epidemiology and Patient Population

5.1. Key Findings

5.2. 7MM Total Diagnosed Incident Patient Population of Glioblastoma Multiforme

6. Country Wise-Epidemiology of Glioblastoma Multiforme

6.1. United States

6.1.1. Assumptions and Rationale

6.1.2. Total Diagnosed Incident Population of Glioblastoma Multiforme in the United States

6.1.3. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States

6.1.4. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States

6.1.5. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United States

6.1.6. Diagnosed Incident Population based on Primary Site of GBM in the United States

6.1.7. Diagnosed Incident Population based on Histologic Classification of GBM Tumor in the United States

6.2. EU5 Countries

6.2.1. Assumptions and Rationale

6.3. Germany

6.3.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in Germany

6.3.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany

6.3.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany

6.3.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Germany

6.3.5. Diagnosed Incident Population based on Primary Site of GBM in Germany

6.3.6. Diagnosed Incident Population based on Histologic Classification of GBM in Germany

6.4. France

6.4.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in France

6.4.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in France

6.4.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in France

6.4.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in France

6.4.5. Diagnosed Incident Population based on Primary Site of GBM in France

6.4.6. Diagnosed Incident Population based on Histologic Classification of GBM in France

6.5. Italy

6.5.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in Italy

6.5.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy

6.5.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy

6.5.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Italy

6.5.5. Diagnosed Incident Population based on Primary Site of GBM in Italy

6.5.6. Diagnosed Incident Population based on Histologic Classification of GBM in Italy

6.6. Spain

6.6.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in Spain

6.6.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain

6.6.3 Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain

6.6.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Spain

6.6.5. Diagnosed Incident Population based on Primary Site of GBM in Spain

6.6.6. Diagnosed Incident Population based on Histologic Classification of GBM in Spain

6.7. United Kingdom

6.7.1. Total Diagnosed Incident Population of Glioblastoma Multiforme in the United Kingdom

6.7.2. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom

6.7.3. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom

6.7.4. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in the United Kingdom

6.7.5. Diagnosed Incident Population based on Primary Site of GBM in the United Kingdom

6.7.6. Diagnosed Incident Population based on Histologic Classification of GBM in the United Kingdom

6.8. Japan

6.8.1. Assumptions and Rationale

6.8.2. Total Diagnosed Incident Population of Glioblastoma Multiforme in Japan

6.8.3. Gender-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan

6.8.4. Type-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan

6.8.5. Age-specific Diagnosed Incidence of Glioblastoma Multiforme in Japan

6.8.6. Diagnosed Incident Population based on Primary Site of GBM in Japan

6.8.7. Diagnosed Incident Population based on Histologic Classification of GBM in Japan

7. Treatment

7.1. Surgery

7.2. Chemotherapy

7.3. Radiation

7.4. Others

7.4.1. Targeted therapy

7.4.2. Tumor treatment fields (TTF)

7.4.3. Immunotherapy

7.5 Management of Symptoms with Medication

8. Treatment Algorithm

9. The American Society of Clinical Oncology (ASCO) Endorsed American Society for Radiation Oncology (ASTRO) Guideline on Radiation Therapy for Glioblastoma

10. The National Comprehensive Cancer Network (NCCN) Guidelines for Glioblastoma

11. Glioblastoma in Adults: A Society for Neuro-Oncology (SNO) and European Society of Neuro-Oncology (EANO) Consensus Review on Current Management and Future Directions

11.1. Medical Management and Supportive Care

11.2. Standard Therapy

11.3. Surgical Management

11.4. Radiotherapy Considerations

11.5. Recurrent Glioblastoma Scenario

12. SEOM (Medical Oncology Spanish Society) Clinical Guidelines for Diagnosis and Treatment of Glioblastoma

13. Recognized Establishments

14. Unmet Needs

15. Marketed Drugs

15.1. Avastin: Genentech

15.1.1. Drug Description

15.1.2. Regulatory Milestones

15.1.3. Other Development Activities

15.1.4. Safety and Efficacy

15.1.5. Product Profile

15.2. Temodar/Temodal: Merck

15.2.1. Drug Description

15.2.2. Regulatory Milestones

15.2.3. Other Development Activities

15.2.4. Safety and Efficacy

15.2.5. Product Profile

16. Emerging Drugs

16.1. Key Cross Competition

16.2. Other emerging therapies in development

16.3. Ofranergene obadenovec (VB-111): VBL Therapeutics

16.3.1. Product Description

16.3.2. Clinical Development

16.3.3. Safety and Efficacy

16.4. Trans Sodium Crocetinate: Diffusion Pharmaceuticals

16.4.1. Product Description

16.4.2. Clinical Development

16.4.3. Safety and Efficacy

16.5. Regorafenib: Bayer

16.5.1. Product Description

16.5.2. Clinical Development

16.5.3. Safety and Efficacy

16.6. Durvalumab (MEDI4736): MedImmune

16.6.1. Product Description

16.6.2. Clinical Development

16.6.3. Safety and Efficacy

16.7. Tasadenoturev (DNX-2401): DNAtrix

16.7.1. Product Description

16.7.2. Clinical Development

16.7.3. Safety and Efficacy

16.8. ONC201: Oncoceutics

16.8.1. Product Description

16.8.2. Clinical Development

16.8.3. Safety and Efficacy

16.9. Selinexor (KPT-330): Karyopharm Therapeutics

16.9.1. Product Description

16.9.2. Clinical Development

16.9.3. Safety and Efficacy

16.10. VBI-1901: VBI Vaccines

16.10.1. Product Description

16.10.2. Clinical Development

16.10.3. Safety and Efficacy

16.11. Paxalisib (GDC-0084): Kazia Therapeutics

16.11.1. Product Description

16.11.2. Clinical Development

16.11.3. Safety and Efficacy

16.12. AV-GBM-1: Aivita Biomedical

16.12.1. Product Description

16.12.2. Clinical Development

16.12.3. Safety and Efficacy

16.13. MDNA55: Medicenna Therapeutics

16.13.1. Product Description

16.13.2. Clinical Development

16.13.3. Safety and Efficacy

16.14. VAL-083 (Dianhydrogalactitol): DelMar Pharmaceuticals

16.14.1. Product Description

16.14.2. Clinical Development

16.14.3. Safety and Efficacy

16.15. ITI-1000 (pp65 DC Vaccine): Immunomic Therapeutics

16.15.1. Product Description

16.15.2. Clinical Development

16.15.3. Safety and Efficacy

16.16. INO-5401+ INO-9012+ Cemiplimab (REGN2810): Inovio Pharmaceuticals

16.16.1. Product Description

16.16.2. Clinical Development

16.16.3. Safety and Efficacy

17. Glioblastoma Multiforme: 7 Major Market Analysis

17.1. Key Findings

17.2. Total Market Size of Glioblastoma Multiforme in the 7 MM

17.3. The United States Market Outlook

17.4. United States Market Size

17.4.1. Total Market size of Glioblastoma Multiforme in the United States

17.4.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.4.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.5. EU-5 Countries: Market Outlook

17.6. Germany

17.6.1. Total Market size of Glioblastoma Multiforme in Germany

17.6.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.6.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.7. France

17.7.1. Total Market Size of Glioblastoma Multiforme in France

17.7.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.7.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.8. Italy

17.8.1. Total Market Size of Glioblastoma Multiforme in Italy

17.8.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.8.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.9. Spain

17.9.1. Total Market Size of Glioblastoma Multiforme in Spain

17.9.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.9.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.1. United Kingdom

17.10.1. Total Market Size of Glioblastoma Multiforme in the United Kingdom

17.10.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.10.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

17.11. Japan: Market Outlook

17.11.1. Total Market Size of Glioblastoma Multiforme in Japan

17.11.2. Market Size of Glioblastoma Multiforme by Current Therapies

17.11.3. Market Size of Glioblastoma Multiforme by Emerging Therapies

18. Market Access and Reimbursement

18.1. United States

18.2. Europe

18.3. Japan

19. Case Reports

19.1. Glioblastoma and intracranial aneurysms: Case report and review of the literature (United States)

19.2. A New Method for Ethical and Efficient Evidence Generation for Off-label Medication Use in Oncology (A Case Study in Glioblastoma) (United Kingdom)

19.3. Diagnosis and treatment of early-stage glioblastoma (Japan)

20. KOL Reviews

21. Market Drivers

22. Market Barriers

23. SWOT Analysis

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

Categories
All News

Chlamydia Infections Pipeline Insights, 2021

Chlamydia Infections Pipeline Insight

DelveInsight’s,Chlamydia Pipeline report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in Chlamydia pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Chlamydia Understanding

Chlamydia: Overview

Chlamydia is a sexually transmitted infection (STI) caused by a bacteria called chlamydia trachomatis. Usually it doesn’t cause any symptoms and can be easily treated with antibiotics. However, if it isn’t treated early it can spread to other parts of your body and lead to long-term health problems.

Chlamydia Emerging Drugs Chapters

This segment of the Chlamydia report encloses its detailed analysis of various drugs in different stages of clinical development, including phase II, I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

Chlamydia Emerging Drugs

  • EVO100: Evofem Biosciences

The investigational drug candidate EVO100 vaginal gel is designed to reduce certain vaginal infections by:

  • Balancing vaginal pH, thereby maintaining healthy vaginal flora and creating an environment that is detrimental to the growth and proliferation of harmful bacteria
  • Using a different mechanism of action that may help to address drug resistance concerns

Further product details are provided in the report

Chlamydia: Therapeutic Assessment

This segment of the report provides insights about the different Chlamydia drugs segregated based on following parameters that define the scope of the report, such as:

  • Major Players in Chlamydia

There are approx. 10+ key companies which are developing the therapies for Chlamydia. The companies which have their Chlamydia drug candidates in the most advanced stage, i.e. phase II include, Evofem Biosciences.

Request for sample pages @ Chlamydia Pipeline Report 

Table of contents

Introduction

Executive Summary

Chlamydia: Overview

• Causes

• Mechanism of Action

• Signs and Symptoms

• Diagnosis

• Disease Management

Pipeline Therapeutics

• Comparative Analysis

Therapeutic Assessment

• Assessment by Product Type

• Assessment by Stage and Product Type

• Assessment by Route of Administration

• Assessment by Stage and Route of Administration

• Assessment by Molecule Type

• Assessment by Stage and Molecule Type

Chlamydia – DelveInsight’s Analytical Perspective

In-depth Commercial Assessment

• Chlamydia companies’ collaborations, Licensing, Acquisition -Deal Value Trends

Chlamydia Collaboration Deals

• Company-Company Collaborations (Licensing / Partnering) Analysis

• Company-University Collaborations (Licensing / Partnering) Analysis

Late Stage Products (Phase III)

• Comparative Analysis

Solithromycin – Melinta Therapeutics

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Mid Stage Products (Phase II)

• Comparative Analysis

Drug Name: Company Name

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Early Stage Products (Phase I)

• Comparative Analysis

Drug Name: Company Name

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Pre-clinical and Discovery Stage Products

• Comparative Analysis

Drug Name: Company Name

• Product Description

• Research and Development

• Product Development Activities

Drug profiles in the detailed report…..

Inactive Products

• Comparative Analysis

Chlamydia Key Companies

Chlamydia Key Products

Chlamydia- Unmet Needs

Chlamydia- Market Drivers and Barriers

Chlamydia- Future Perspectives and Conclusion

Chlamydia Analyst Views

Chlamydia Key Companies

Appendix

Categories
All News

Bone Grafts and Substitutes Market Insights, Competitive Landscape and Market Forecast

What are Bone Grafts and Substitutes?

Bone grafting is a medical technique that is done to resolve bone associated disorders. The process involves transplanting bone tissue to increase and regenerate bones lost due to medical reasons or accident.

DelveInsight, a market research and business consulting has launched Bone Grafts and Substitutes Market Insights, Competitive Landscape and Market Forecast – 2025’ report delivers an in-depth understanding of Bone Grafts and Substitutes and the historical and forecasted Bone Grafts and Substitutes market trends in the US, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan.

The Bone Grafts and Substitutes market report provides an overview of Bone Grafts and Substitutes, reasons to get Bone Grafts and Substitutes as well as its advantages and limitations. Additionally, the report provides insight on the Bone Grafts and Substitutes market share of the individual Bone Grafts and Substitutes devices, current and forecasted Bone Grafts and Substitutes market size from 2017 to 2025 segmented by seven major markets. The report also covers the market drivers, market barriers and unmet medical needs to curate best of the opportunities and assesses underlying potential of the market.

What are Bone Grafts and Substitutes market drivers?

The key factors driving Bone Grafts and Substitutes market growth are the rise in the number of bone grafting operations, an increasing ageing population with demand for high-quality musculoskeletal function in old age and expanded penetration of orthopaedic specialty hospitals and health insurance.

What are Bone Grafts and Substitutes market barriers?

Bone Grafts and Substitutes market development is limited by the risk and complications of bone grafting procedures and by the high cost of bone graft care.

How will Bone Grafts and Substitutes market change in the future?

As per DelveInsight’s estimates, Bone Grafts and Substitutes Market across 7MM is expected to rise at a significant CAGR in the study period (2017 to 2025).

To know more information, click here @ Bone Grafts and Substitutes Market Analysis  

How many companies are working for Bone Grafts and Substitutes market?

The companies such as Arthrex, Inc., Baxter International Inc., Integra LifeSciences Holdings Corporation, Johnson & Johnson (DePuy Synthes), Medtronic Plc., Musculoskeletal Transplant Foundation, NuVasive, Inc., Stryker Corporation, Wright Medical Group N.V., and Zimmer Biomet Holdings, Inc, and many others are working for Bone Grafts and Substitutes market.

Scope of the Bone Grafts and Substitutes Market Research Report

  • The report covers the descriptive overview of Bone Grafts and Substitutes, explaining its applications, advantages, and limitations, etc.
  • Additionally, an all-inclusive account of the currently available Bone Grafts and Substitutes is provided, which will have an impact on the future market of Bone Grafts and Substitutes.
  • A detailed review of Bone Grafts and Substitutes market; historical and forecasted market size is included in the report, covering devices outreach in the 7MM.
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Bone Grafts and Substitutes market.

Request for sample pages to know more on Bone Grafts and Substitutes Competitive Analysis

 

 

 

Categories
All News

Adalimumab Biosimilars Insight

Adalimumab, sold under the brand name Humira among others, is a medication used to treat rheumatoid arthritis, psoriatic arthritis, ankylosing spondylitis, Crohn’s disease, ulcerative colitis, psoriasis, hidradenitis suppurativa, uveitis, and juvenile idiopathic arthritis. It works by blocking a protein (tumor necrosis factor or TNF) found in the body’s immune system that causes joint swelling and damage in arthritis as well as red scaly patches in psoriasis.

DelveInsight’s, “Adalimumab Biosimilar Insight” report provides comprehensive insights about 35+ companies and 45+ marketed and pipeline drugs in Adalimumab Biosimilars landscape. It covers the marketed and pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

Adalimumab Biosimilars Emerging Drugs

  • IBI303: Innovent Biologics

IBI303 is a recombinant human monoclonal antibody of TNF-α, which has the same amino acid sequence as branded adalimumab (Humira) and shows high degrees of similarity in respect to: chemical properties, in vitro biological activity (binding affinity and neutralizing activity against TNF-α), potency, and PK/PD. Pharmacologic and toxicologic studies of IBI303 also showed high similarity to Humira. Clinical studies have demonstrated that IBI303 can significantly alleviate the symptoms and physical signs of AS and decrease the disease activity and enthesitis, while improving both somatic motor ability and mobility of spine in patients with AS. It also improved the quality of life in patients with AS and reduced the disease’s impact on their activities of daily life. IBI303 also generated an acceptable safety profile with most of the adverse events graded as mild or moderate. IBI303 may meet Chinese patients’ urgent needs with an affordable price at global quality standards.

 

  • CT-P17: Celltrion

CT-P17 is the first high-concentration type of medicine for a biosimilar made of adalimumab. The company has differentiated CT-P17 from existing Humira biosimilars by halving the dosage. By taking the latest trend into account, Celltrion has also removed citrate, which can cause pain in self-injection, from its latest product. If Celltrion launches CT-P17, it will be able to complete a robust portfolio of CT-P17 in the global autoimmune disorder treatment market.

 

Further product details are provided in the report. Request @ Adalimumab Biosimilars Drugs

 

Report Highlights

  • The companies and academics are working to assess challenges and seek opportunities that could influence Adalimumab R&D. The therapies under development are focused on novel approaches to treat/improve Adalimumab.
  • In July 2020, the FDA has approved an adalimumab biosimilar (Hulio) from Fujifilm Kyowa Kirin Biologics, making it the sixth adalimumab biosimilar to AbbVie’s reference product Humira that has been approved and the 28th biosimilar approved by the FDA. Mylan will handle the commercialization in the United States.
  • In March 2020, Alvotech announced that it entered into an exclusive license partnership with DKSH, a market expansion services provider, for the commercialization of AVT02, a biosimilar to AbbVie’s HUMIRA (adalimumab), in selected Asia-Pacific (APAC) markets.
  • In October 2018, Orion Corporation and Amgen have signed an agreement for the marketing and sales of AMGEVITA, Finland’s first adalimumab biosimilar. Based on its sales value, the original adalimumab product is the most-sold medicine globally and in Finland, and its impact on medicine reimbursement costs is substantial.

How many key players are involved in Adalimumab Biosimilars development?

Zydus Cadila, Tanvex Biopharma, Synermore Biologics, Shanghai Henlius Biotech, Sandoz, Samsung Bioepis, Prestige BioPharma, PlantPraxis, Pfizer, Outlook Therapeutics, Mylan, and others are involved in Adalimumab biosimilars.

Request sample report @ Adalimumab Biosimilars Key Players

 

Categories
All News

Corneal Endothelial Dystrophy (CDE) Market, Epidemiology, and Market Forecast Analysis -2030

Corneal Endothelial Dystrophy Market 

DelveInsight’s ‘Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Corneal Endothelial Dystrophy (CED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

The Corneal Endothelial Dystrophy (CED) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Corneal Endothelial Dystrophy (CED) symptoms market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Corneal Endothelial Dystrophy (CED) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Corneal Endothelial Dystrophy (CED) Overview

Corneal dystrophies are a group of rare genetic diseases that affect the cornea, the front part of your eye. There are more than 20 types, each with different symptoms, all-cause a buildup of foreign material in one or more layers of your cornea. Over time, your vision may become cloudy or blurry.

Corneal Endothelial Dystrophy (CED) Market Outlook

The Corneal Endothelial Dystrophy market outlook of the report helps build the detailed comprehension of the historic, current, and forecasted Corneal Endothelial Dystrophy (CED) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.

This segment gives a thorough detail of Corneal Endothelial Dystrophy (CED) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Corneal Endothelial Dystrophy market in 7MM is expected to grow in the study period 2017–2030.

Key Findings

This section includes a glimpse of the Corneal Endothelial Dystrophy (CED) market in 7MM. The market size of Corneal Endothelial Dystrophy (CED) in the seven major markets was found to be USD 5.75 Million in 2017.

Scope of the Report

  • The report covers the descriptive overview of Corneal Endothelial Dystrophy (CED), explaining its causes, signs and symptoms, physiology, and currently available therapies
  • Comprehensive insight has been provided into the Corneal Endothelial Dystrophy (CED) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Corneal Endothelial Dystrophy (CED) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Corneal Endothelial Dystrophy (CED) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Corneal Endothelial Dystrophy (CED) market

Report Highlights

  • In the coming years, Corneal Endothelial Dystrophy (CED) market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Corneal Endothelial Dystrophy (CED) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Corneal Endothelial Dystrophy (CED). The launch of emerging therapies will significantly impact the Corneal Endothelial Dystrophy (CED) market
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I/II, and II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Request for sample pages @ Corneal Endothelial Dystrophy Market Report 

Table of contents

1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 Corneal Endothelial Dystrophy (CED): Market Overview at a Glance

5.1 Total Market Share (%) Distribution of Corneal Endothelial Dystrophy (CED) in 2017

5.2 Total Market Share (%) Distribution of Corneal Endothelial Dystrophy (CED) in 2030

6 Corneal Endothelial Dystrophy (CED): Market Overview at a Glance

6.1 Introduction

6.2 Types of Corneal Dystrophies

6.3 Stages of Fuchs endothelial dystrophy

6.4 Causes

6.5 Signs and Symptoms

6.6 Genetics and Inheritance

6.7 Clinical Presentation

6.8 Pathophysiology

6.9 Prognosis

6.1 Diagnosis

6.10.1 Diagnostic criteria

6.10.2 Differential Diagnosis

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Assumptions and Rationale

7.3 Total cases of Corneal Endothelial Dystrophy (CED) in 7MM

7.4 United States

7.4.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in the United States

7.4.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in the United States

7.4.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in the United States

7.4.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in the United States

7.5 EU5 Countries

7.6 Germany

7.6.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Germany

7.6.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Germany

7.6.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Germany

7.6.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Germany

7.7 France

7.7.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in France

7.7.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in France

7.7.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in France

7.7.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in France

7.8 Italy

7.8.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Italy

7.8.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Italy

7.8.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Italy

7.8.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Italy

7.9 Spain

7.9.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Spain

7.9.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Spain

7.9.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Spain

7.9.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Spain

7.10. UK

7.10.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom

7.10.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom

7.10.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom

7.10.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom

7.11 Japan

7.11.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Japan

7.11.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Japan

7.11.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Japan

7.11.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Japan

8 Treatment of Corneal Endothelial Dystrophy (CED)

9 Unmet Needs

10 Marketed Drugs

10.1 Rhopressa: Aerie Pharmaceuticals

10.1.1 Drug Description

10.1.2 Regulatory Milestones

10.1.3 Other Development Activities

10.1.4 Clinical Development

10.1.5 Safety and Efficacy

10.1.6 Product Profile

11 Emerging Therapies

11.1 Key Cross Competition

11.2 Ripasudil Hydrochloride Hydrate: Kowa Pharmaceuticals

11.2.1 Drug Description

11.2.2 Other Development Activities

11.2.3 Clinical Development

11.2.4 Product Profile

11.3 TTHX 1114: Trefoil Therapeutics

11.3.1 Drug Description

11.3.2 Other Development Activities

11.3.3 Clinical Development

11.3.4 Product Profile

12 Corneal Endothelial Dystrophy (CED): 7 Major Market Analysis

12.1 Key Findings

12.2 Market Size of Corneal Endothelial Dystrophy (CED) in 7MM

13 Seven Major Market Outlook

14 United States Market Size

14.1 Total Market Size of Corneal Endothelial Dystrophy (CED) in the United States

14.2 Total Market Size of Corneal Endothelial Dystrophy (CED) by Therapies in the United States

14.3 Germany

14.3.1 Total market size of Corneal Endothelial Dystrophy (CED) in Germany

14.3.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in Germany

14.4 France

14.4.1 Total market size of Corneal Endothelial Dystrophy (CED) in France

14.4.2 Total Market size of Corneal Endothelial Dystrophy (CED) by Therapies in France

14.5 Italy

14.5.1 Total market size of Corneal Endothelial Dystrophy (CED) in Italy

14.5.2 Total Market size of Corneal Endothelial Dystrophy (CED) by Therapies in Italy

14.6 Spain

14.6.1 Total Market Size of Corneal Endothelial Dystrophy (CED) in Spain

14.6.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in Spain

14.7 United Kingdom

14.7.1 Total market size of Corneal Endothelial Dystrophy (CED) in the United Kingdom

14.7.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in the UK

14.8 Japan

14.8.1 Total market size of Corneal Endothelial Dystrophy (CED) in Japan

14.8.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in Japan

15 Market Drivers

16 Market Barriers

17 SWOT Analysis

18 Market Access

19 Case Study

19.1 A case study of a patient with atypical regressive corneal endothelial cysts in long-term confocal follow-up

19.2 A case study of endothelial keratoplasty for posterior polymorphous corneal dystrophy in a 4-month-old infant

19.3 A case study of eventual endothelial failure after initial corneal clearing after a detached endothelial graft in Fuchs dystrophy

20 KOL Views

21 Appendix

21.1 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

Categories
All News

Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2030

DelveInsight’s ‘Follicular Lymphoma Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology as well as the market trends of Follicular Lymphoma in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan.

What is Follicular Lymphoma?

Follicular lymphoma, a B-cell lymphoma, is the second most common type of low-grade non-Hodgkin lymphoma (NHL). The transformation of a B-cell characterizes it into a malignant cell. Abnormal, uncontrolled growth and proliferation of malignant B-cells can lead to enlargement of specific lymph node regions; involvement of other lymphatic tissues such as the spleen or bone marrow; and spread to other bodily tissues and organs.

 What are Follicular Lymphoma causes?

Follicular Lymphoma causes are not known. Unlike some cancers, they are not passed down in families. In some cases, radiation or cancer-causing chemicals, or certain infections, may be a cause. But other times there is no known cause.

What are the symptoms of Follicular Lymphoma?

Follicular Lymphoma symptoms include painless swelling of the lymph nodes in your neck, groin, stomach, or armpits, shortness of breath, fatigue, night sweats, and weight loss.

How Follicular Lymphoma affected population?

Follicular Lymphoma Epidemiology

  • According to DelveInsight’s analysis, the total prevalent population of Follicular Lymphoma in seven major markets was 33,363 in 2017. These cases are expected to increase with a significant CAGR during the study period (2017–2030).
  • Among all the seven major markets, the United States accounts for the highest number of Follicular Lymphoma cases.
  • In the US, the Follicular Lymphoma cases were 14,329 in 2017. Moreover, the grade-specific cases of Follicular Lymphoma were highest among grade I and were reported to be 5,198 cases.

To know more, request sample pages @Follicular Lymphoma Market Landscape

Follicular Lymphoma Market Outlook

According to DelveInsight, the Follicular Lymphoma market size is expected to increase at a significant CAGR during the study period (2017–2030). Among all the seven major markets, the United States accounts for the largest Follicular Lymphoma market size with USD 799 million in 2017, while Spain had the smallest market size of Follicular Lymphoma with USD 56 million in 2017.

What are the present Follicular Lymphoma market drivers?

Changing standards of care, increasing opportunities and family history aims at driving the market growth.

What are the Follicular Lymphoma market barriers?

Clinical heterogeneity, economic burden of the disease and adverse effects of the therapies are some limitations to the Follicular Lymphoma Market Growth.

Which are the leading companies in Follicular Lymphoma market?

Key Players such as Epizyme, Kite Pharma, Novartis, Roche, Regeneron, TG therapeutics, MEI Pharma, Incyte Corporation, Bayer Health, Verastem Oncology, Gilead Sciences, Xynomics Pharmaceuticals, Bristol Myeres, Takeda Oncology, and others are the leading companies in Follicular Lymphoma market.

Request sample pages for more information on Follicular Lymphoma Market Size

Table of contents

1. Key Insights

2. Executive Summary of Follicular Lymphoma

3. SWOT Analysis for Follicular Lymphoma

4. Follicular Lymphoma Market Overview at a Glance

4.1. Market Share (%) Distribution of Follicular Lymphoma in 2018

4.2. Market Share (%) Distribution of Follicular Lymphoma in 2030

5. Disease Background and Overview

5.1. Introduction

5.2. Types of Follicular Lymphoma

5.3. Sign and Symptoms

5.4. Causes

5.5. Staging and Grading

5.6. Genetic Landscape of Follicular Lymphoma

5.7. Pathophysiology

5.8. Diagnosis

6. Epidemiology and Patient Population

6.1. Key Findings

6.2. 7MM Total Incident Patient Population of Follicular Lymphoma

7. Country Wise-Epidemiology of Follicular Lymphoma

7.1. Assumptions and Rationale – 7MM

7.2. The United States

7.2.1. Total Incident Cases of Follicular Lymphoma in the United States

7.2.2. Grade-specific Cases of Follicular Lymphoma in the United States

7.2.3. Age-specific Cases of Follicular Lymphoma in the United States

7.2.4. Stage-specific Cases of Follicular Lymphoma in the United States

7.3. EU5

7.3.1. Germany

7.3.1.1. Total Incident Cases of Follicular Lymphoma in Germany

7.3.1.2. Grade-specific Cases of Follicular Lymphoma in Germany

7.3.1.3. Age-specific Cases of Follicular Lymphoma in Germany

7.3.1.4. Stage-specific Cases of Follicular Lymphoma in Germany

7.3.2. France

7.3.2.1. Total Incident Cases of Follicular Lymphoma in France

7.3.2.2. Grade-specific Cases of Follicular Lymphoma in France

7.3.2.3. Age-specific Cases of Follicular Lymphoma in France

7.3.2.4. Stage-specific Cases of Follicular Lymphoma in France

7.3.3. Italy

7.3.3.1. Total Incident Cases of Follicular Lymphoma in Italy

7.3.3.2. Grade-specific Cases of Follicular Lymphoma in Italy

7.3.3.3. Age-specific Cases of Follicular Lymphoma in Italy

7.3.3.4. Stage-specific Cases of Follicular Lymphoma in Italy

7.3.4. Spain

7.3.4.1. Total Incident Cases of Follicular Lymphoma in Spain

7.3.4.2. Grade-specific Cases of Follicular Lymphoma in Spain

7.3.4.3. Age-specific Cases of Follicular Lymphoma in Spain

7.3.4.4. Stage-specific Cases of Follicular Lymphoma in Spain

7.3.5. The United Kingdom

7.3.5.1. Total Incident Cases of Follicular Lymphoma in the United Kingdom

7.3.5.2. Grade-specific Cases of Follicular Lymphoma in the United Kingdom

7.3.5.3. Age-specific Cases of Follicular Lymphoma in the UK

7.3.5.4. Stage-specific Cases of Follicular Lymphoma in the UK

7.4. Japan

7.4.1. Total Incident Cases of Follicular Lymphoma in Japan

7.4.2. Grade-specific Cases of Follicular Lymphoma in Japan

7.4.3. Age-specific Cases of Follicular Lymphoma in Japan

7.4.4. Stage-specific Cases of Follicular Lymphoma in Japan

8. Treatment

9. Guidelines

9.1. NCCN Guidelines for Patient with Follicular Lymphoma

9.2. ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up: Newly diagnosed and relapsed follicular lymphoma

9.3. Japanese Society of Hematology (JSH) practical guidelines for Follicular lymphoma

10. Unmet Needs

11. Organizations contributing toward Follicular Lymphoma

12. Patient Journey

12.1. A Journey through follicular lymphoma

12.2. Patient Journey: General

13. Case Reports

13.1. Patient Case Study: From Follicular Lymphoma to DLBCL

13.2. Diagnostic Workup for Follicular Lymphoma

13.3. A case study of t(14;22)(q32;q11) involving immunoglobulin heavy and light chain in follicular lymphoma

14. Marketed Therapies

14.1. Tazverik: Epizyme

14.1.1. Product Description

14.1.2. Other Development Activities

14.1.3. Clinical Development

14.1.4. Safety and Efficacy

14.2. Aliqopa: Bayer Healthcare Pharmaceuticals

14.2.1. Product Description

14.2.2. Other Development Activities

14.2.3. Clinical Development

14.2.4. Safety and Efficacy

14.3. Copiktra: Verastem Oncology

14.3.1. Product Description

14.3.2. Other Development Activities

14.3.3. Clinical Development

14.3.4. Safety and Efficacy

14.4. Zydelig: Gilead Sciences

14.4.1. Product Description

14.4.2. Other Development Activities

14.4.3. Clinical Development

14.4.4. Safety and Efficacy

15. Combinational Therapies: Marketed

16. Emerging Therapies

16.1. Abexinostat: Xynomic Pharmaceuticals, Inc.

16.1.1. Product Description

16.1.2. Other Development Activities

16.1.3. Clinical Development

16.1.4. Safety and Efficacy

16.2. Umbralisib: TG Therapeutics

16.2.1. Product Description

16.2.2. Other Development Activities

16.2.3. Clinical Development

16.2.4. Safety and Efficacy

16.3. ME-401: MEI Pharma

16.3.1. Product Description

16.3.2. Other Development Activities

16.3.3. Clinical Development

16.3.4. Safety and Efficacy

16.4. Odronextamab: Regeneron Pharmaceuticals

16.4.1. Product Description

16.4.2. Other Development Activities

16.4.3. Clinical Development

16.4.4. Safety and Efficacy

16.5. Parsaclisib: Incyte Corporation

16.5.1. Product Description

16.5.2. Other Development Activities

16.5.3. Clinical Development

16.5.4. Safety and Efficacy

16.6. Kymriah: Novartis

16.6.1. Product Description

16.6.2. Other Development Activities

16.6.3. Clinical Development

16.7. Yescarta: Kite Pharma

16.7.1. Product Description

16.7.2. Other Development Activities

16.7.3. Clinical Development

16.7.4. Safety and Efficacy

16.8. Nivolumab: Bristol-Myers Squibb

16.8.1. Product Description

16.8.2. Other Development Activities

16.8.3. Clinical Development

16.8.4. Safety and Efficacy

16.9. Ixazomib – Takeda Oncology

16.9.1. Product Description

16.9.2. Other Development Activities

16.9.3. Clinical Development

16.9.4. Safety and Efficacy

17. Emerging Combinational Therapies

17.1. Ibrutinib + Rituximab

17.2. Umbralisib + Ublituximab + Bendamustine

17.3. Zanubrutinib + Obinutuzumab

18. Other Promising Therapies

18.1. Atezolizumab: Roche

18.1.1. Product Description

18.1.2. Other Development Activities

18.1.3. Clinical Development

18.1.4. Safety and Efficacy

18.2. Pembrolizumab: Merck

18.2.1. Product Description

18.2.2. Other Development Activities

18.2.3. Clinical Development

18.2.4. Safety and Efficacy

18.3. Venetoclax – AbbVie/Genentech

18.3.1. Product Description

18.3.2. Other Development Activities

18.3.3. Clinical Development

18.3.4. Safety and Efficacy

18.4. Betalutin: Nordic Nanovector ASA

18.4.1. Product Description

18.4.2. Other Development Activities

18.4.3. Clinical Development

18.4.4. Safety and Efficacy

18.5. Tenalisib: Rhizen Pharmaceuticals

18.5.1. Product Description

18.5.2. Other Development Activities

18.5.3. Clinical Development

18.5.4. Safety and Efficacy

19. Follicular Lymphoma: Seven Major Market Analysis

19.1. Key Findings

19.2. Market Size of Follicular Lymphoma in 7MM

20. Market Outlook

20.1. 7MM Market Outlook

20.2. United States Market Size

20.3. EU-5 Countries: Market Outlook

20.3.1. Germany

20.3.2. France

20.3.3. Italy

20.3.4. Spain

20.3.5. United Kingdom

20.4. Japan: Market Outlook

20.4.1. Total Market Size of Follicular Lymphoma

20.4.2. Market Size of Follicular Lymphoma by Therapies

21. Market Drivers

22. Market Barriers

23. Market Access and Reimbursement

24. Appendix

24.1. Bibliography

24.2. Report Methodology

25. DelveInsight Capabilities

26. Disclaimer

27. About DelveInsight

Categories
All News

Corneal Endothelial Dystrophy Market, Epidemiology, and Market Forecast-2030

DelveInsight’s ‘Corneal Endothelial Dystrophy Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Corneal Endothelial Dystrophy (CED), historical and forecasted epidemiology as well as the market trends in the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom), and Japan.

Corneal Endothelial Dystrophy Market 

The Corneal Endothelial Dystrophy (CED) market report provides current treatment practices, emerging drugs and their market share of the individual therapies, current and forecasted Corneal Endothelial Dystrophy (CED) symptoms market size from 2017 to 2030 segmented by seven major markets.

The report also covers current Corneal Endothelial Dystrophy (CED) symptoms treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Corneal Endothelial Dystrophy (CED) Overview

Corneal dystrophies are a group of rare genetic diseases that affect the cornea, the front part of your eye. There are more than 20 types, each with different symptoms, all-cause a buildup of foreign material in one or more layers of your cornea. Over time, your vision may become cloudy or blurry.

Corneal Endothelial Dystrophy (CED) Market Outlook

The Corneal Endothelial Dystrophy market outlook of the report helps build the detailed comprehension of the historic, current, and forecasted Corneal Endothelial Dystrophy (CED) market trends by analyzing the impact of current therapies on the market, unmet needs, drivers, and barriers and demand of better technology.

This segment gives a thorough detail of Corneal Endothelial Dystrophy (CED) market trend of each marketed drug and early-stage pipeline therapy by evaluating their impact based on the annual cost of therapy, inclusion and exclusion criteria’s, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight.

According to DelveInsight, Corneal Endothelial Dystrophy market in 7MM is expected to grow in the study period 2017–2030.

Key Findings

This section includes a glimpse of the Corneal Endothelial Dystrophy (CED) market in 7MM. The market size of Corneal Endothelial Dystrophy (CED) in the seven major markets was found to be USD 5.75 Million in 2017.

Scope of the Report

  • The report covers the descriptive overview of Corneal Endothelial Dystrophy (CED), explaining its causes, signs and symptoms, physiology, and currently available therapies
  • Comprehensive insight has been provided into the Corneal Endothelial Dystrophy (CED) epidemiology and treatment in the 7MM
  • Additionally, an all-inclusive account of both the current and emerging therapies for Corneal Endothelial Dystrophy (CED) is provided, along with the assessment of new therapies, which will have an impact on the current treatment landscape
  • A detailed review of the Corneal Endothelial Dystrophy (CED) market; historical and forecasted is included in the report, covering drug outreach in the 7MM
  • The report provides an edge while developing business strategies, by understanding trends shaping and driving the global Corneal Endothelial Dystrophy (CED) market

Report Highlights

  • In the coming years, Corneal Endothelial Dystrophy (CED) market is set to change due to the rising awareness of the disease, and Favorable Environment for New Anti-infective Modalities; which would expand the size of the market to enable the drug manufacturers to penetrate more into the market
  • The companies and academics are working to assess challenges and seek opportunities that could influence Corneal Endothelial Dystrophy (CED) R&D. The therapies under development are focused on novel approaches to treat/improve the disease condition
  • Major players are involved in developing therapies for Corneal Endothelial Dystrophy (CED). The launch of emerging therapies will significantly impact the Corneal Endothelial Dystrophy (CED) market
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase I/II, and II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, key cross-competition, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities

Request for sample pages @ Corneal Endothelial Dystrophy Market Report 

Table of contents

1 Key Insights

2 Executive summary

3 Organizations

4 Epidemiology and Market Methodology

5 Corneal Endothelial Dystrophy (CED): Market Overview at a Glance

5.1 Total Market Share (%) Distribution of Corneal Endothelial Dystrophy (CED) in 2017

5.2 Total Market Share (%) Distribution of Corneal Endothelial Dystrophy (CED) in 2030

6 Corneal Endothelial Dystrophy (CED): Market Overview at a Glance

6.1 Introduction

6.2 Types of Corneal Dystrophies

6.3 Stages of Fuchs endothelial dystrophy

6.4 Causes

6.5 Signs and Symptoms

6.6 Genetics and Inheritance

6.7 Clinical Presentation

6.8 Pathophysiology

6.9 Prognosis

6.1 Diagnosis

6.10.1 Diagnostic criteria

6.10.2 Differential Diagnosis

7 Epidemiology and Patient Population

7.1 Key Findings

7.2 Assumptions and Rationale

7.3 Total cases of Corneal Endothelial Dystrophy (CED) in 7MM

7.4 United States

7.4.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in the United States

7.4.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in the United States

7.4.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in the United States

7.4.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in the United States

7.5 EU5 Countries

7.6 Germany

7.6.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Germany

7.6.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Germany

7.6.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Germany

7.6.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Germany

7.7 France

7.7.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in France

7.7.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in France

7.7.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in France

7.7.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in France

7.8 Italy

7.8.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Italy

7.8.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Italy

7.8.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Italy

7.8.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Italy

7.9 Spain

7.9.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Spain

7.9.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Spain

7.9.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Spain

7.9.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Spain

7.10. UK

7.10.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom

7.10.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom

7.10.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom

7.10.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in the United Kingdom

7.11 Japan

7.11.1 Total Prevalent cases of Corneal Endothelial Dystrophy (CED) in Japan

7.11.2 Gender-specific cases of Corneal Endothelial Dystrophy (CED) in Japan

7.11.3 Age-specific cases of Corneal Endothelial Dystrophy (CED) in Japan

7.11.4 Type-specific cases of Corneal Endothelial Dystrophy (CED) in Japan

8 Treatment of Corneal Endothelial Dystrophy (CED)

9 Unmet Needs

10 Marketed Drugs

10.1 Rhopressa: Aerie Pharmaceuticals

10.1.1 Drug Description

10.1.2 Regulatory Milestones

10.1.3 Other Development Activities

10.1.4 Clinical Development

10.1.5 Safety and Efficacy

10.1.6 Product Profile

11 Emerging Therapies

11.1 Key Cross Competition

11.2 Ripasudil Hydrochloride Hydrate: Kowa Pharmaceuticals

11.2.1 Drug Description

11.2.2 Other Development Activities

11.2.3 Clinical Development

11.2.4 Product Profile

11.3 TTHX 1114: Trefoil Therapeutics

11.3.1 Drug Description

11.3.2 Other Development Activities

11.3.3 Clinical Development

11.3.4 Product Profile

12 Corneal Endothelial Dystrophy (CED): 7 Major Market Analysis

12.1 Key Findings

12.2 Market Size of Corneal Endothelial Dystrophy (CED) in 7MM

13 Seven Major Market Outlook

14 United States Market Size

14.1 Total Market Size of Corneal Endothelial Dystrophy (CED) in the United States

14.2 Total Market Size of Corneal Endothelial Dystrophy (CED) by Therapies in the United States

14.3 Germany

14.3.1 Total market size of Corneal Endothelial Dystrophy (CED) in Germany

14.3.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in Germany

14.4 France

14.4.1 Total market size of Corneal Endothelial Dystrophy (CED) in France

14.4.2 Total Market size of Corneal Endothelial Dystrophy (CED) by Therapies in France

14.5 Italy

14.5.1 Total market size of Corneal Endothelial Dystrophy (CED) in Italy

14.5.2 Total Market size of Corneal Endothelial Dystrophy (CED) by Therapies in Italy

14.6 Spain

14.6.1 Total Market Size of Corneal Endothelial Dystrophy (CED) in Spain

14.6.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in Spain

14.7 United Kingdom

14.7.1 Total market size of Corneal Endothelial Dystrophy (CED) in the United Kingdom

14.7.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in the UK

14.8 Japan

14.8.1 Total market size of Corneal Endothelial Dystrophy (CED) in Japan

14.8.2 Total market size of Corneal Endothelial Dystrophy (CED) by Therapies in Japan

15 Market Drivers

16 Market Barriers

17 SWOT Analysis

18 Market Access

19 Case Study

19.1 A case study of a patient with atypical regressive corneal endothelial cysts in long-term confocal follow-up

19.2 A case study of endothelial keratoplasty for posterior polymorphous corneal dystrophy in a 4-month-old infant

19.3 A case study of eventual endothelial failure after initial corneal clearing after a detached endothelial graft in Fuchs dystrophy

20 KOL Views

21 Appendix

21.1 Report Methodology

22 DelveInsight Capabilities

23 Disclaimer

24 About DelveInsight

Categories
All News

Bipolar Disorder Market, Epidemiology and Market Forecast -2030

DelveInsight’s ‘Bipolar Disorder Market Insights, Epidemiology, and Market Forecast—2030’ report delivers an in-depth understanding of the Bipolar Disorder (Manic Depression), historical and forecasted epidemiology as well as the Bipolar Disorder (Manic Depression) market trends in the United States, EU5 (Germany, France, Italy, Spain, and the United Kingdom), and Japan. 

Bipolar Disorder Manic Depression Market

The Bipolar Disorder (Manic Depression) market report provides current treatment practices, emerging drugs, Bipolar Disorder (Manic Depression) market share of the individual therapies, current and forecasted Bipolar Disorder (Manic Depression) market size from 2017 to 2030 segmented by seven major markets. The Report also covers current Bipolar Disorder (Manic Depression) treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the market.

Geography Covered

  • The United States
  • EU5 (Germany, France, Italy, Spain, and the United Kingdom)
  • Japan

Bipolar Disorder (Manic Depression) Overview

Bipolar disorder (BD), previously known as manic depressive illness or manic depression, is a mental disorder characterized by wide mood swings from high (manic) to low (depressed). In manic episodes, a person can be delighted, irritable, and there is a marked increase in activity level, whereas, in depressive episodes, someone might feel sad, indifferent, or hopeless, in combination with a deficient activity level. Hypomanic episodes are also seen in patients, and it is a less severe form of mania. It is divided mainly into four subtypes BD-I, BD-II, cyclothymic disorder, and BD not otherwise specified (BD-NOS); the classification is based on the characteristics of mood swings.

Bipolar Disorder (Manic Depression) Epidemiology

The Bipolar Disorder (Manic Depression) epidemiology division provides insights about the historical and current Bipolar Disorder (Manic Depression) patient pool and forecasted trends for every seven major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of the DelveInsight report also provides the diagnosed patient pool and their trends along with assumptions undertaken.

Key Findings

  • In the year 2020, the total diagnosed prevalent case of Bipolar Disorder (Manic Depression) was 3,552,076 cases in the 7MM which are expected to grow during the study period, i.e., 2017–2030.
  • The disease epidemiology covered in the report provides historical as well as forecasted Bipolar Disorder (Manic Depression) epidemiology [segmented as Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression), Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression), Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression), and Total Treated Cases of Bipolar Disorder (Manic Depression)] in the 7MM covering the United States, EU5 countries (Germany, France, Italy, Spain, and the United Kingdom), and Japan from 2017 to 2030.

Bipolar Disorder Emerging Drugs

Lumateperone/ITI-007 (Intra-Cellular Therapies)

Lumateperone (ITI-007) is an investigational, first-in-class small molecule that provides selective and simultaneous modulation of serotonin, dopamine, and glutamate, three neurotransmitter pathways implicated in severe mental illness. It is a potent serotonin 5-HT2A receptor antagonist, a dopamine receptor phosphoprotein modulator (DPPM) acting as a presynaptic partial agonist and postsynaptic antagonist at dopamine D2 receptors, a dopamine D1 receptor-dependent indirect modulator of glutamate (both NDMA and AMPA), and a serotonin reuptake inhibitor. Currently, lumateperone is in Phase III clinical development as a novel treatment for Bipolar Disorder (Manic Depression). Lumateperone Bipolar Disorder (Manic Depression) clinical program consists of three monotherapy studies and one adjunctive study. The company submitted the sNDA to the US FDA in February 2021, and if approved, this drug would be the first therapy indicated for the treatment of depressive episodes associated with bipolar I or II disorder both as monotherapy and as adjunctive therapy in adults

NRX-100/NRX-101 (NeuroRx)

NeuroRx is developing a sequential therapy consisting of intravenous NRX-100 (ketamine HCL) for rapid stabilization of symptoms of depression and suicidal ideation followed by oral NRX-101 (fixed-dose combination of D-cycloserine and lurasidone) for maintenance of stabilization from symptoms of depression and suicidal ideation. NRX-101 is a proprietary, oral fixed-dose combination of two FDA-approved drugs: D-cycloserine, an NMDA receptor modulator; and Lurasidone (Latuda), a 5-HT2a receptor antagonist. NRX-101’s proprietary dual-mechanism of action targets the NMDA and 5-HT2a receptors – two key receptors in the brain. Currently, the molecule is under investigation in Phase III clinical trial for rapid stabilization of acute suicidal ideation and behavior in patients with Bipolar Disorder (Manic Depression). Additionally, the company is also initiating a Phase IIb/III clinical trial of NRX-100/NRX-101 to treat Bipolar Disorder (Manic Depression) in patients with ASIB. In September 2017, the US FDA granted fast track designation to NRX-100 (ketamine HCl) followed by NRX-101 (D-cycloserine + lurasidone) for Bipolar Disorder (Manic Depression) with suicidal ideation.

SEP-4199 (Sunovion/Sumitomo Dainippon Pharma)

SEP-4199 is a nonracemic ratio of amisulpride enantiomers with the potential to be the first benzamide treatment available in the US for mood disorders. Sunovion discovered that the pharmacology of amisulpride is enantiomer-specific and that increasing the ratio of R-amisulpride to S-amisulpride increases the potency for serotonin 5-HT7 receptors relative to dopamine D2 receptors. SEP-4199 was designed to increase levels of serotonin 5-HT7 activity intended to enhance antidepressant efficacy and produce reduced levels of D2 receptor occupancy appropriate for the treatment of Bipolar Disorder (Manic Depression). The pharmacological effect of SEP-4199 is distinct from racemic amisulpride, which is approved in several countries outside the US for the treatment of schizophrenia and other psychiatric condition.

Brexpiprazole (Lundbeck/Otsuka Pharmaceutical)

Brexpiprazole is a molecule discovered by Otsuka and co-developed by Otsuka and Lundbeck. Brexpiprazole is an atypical antipsychotic agent with a partial dopamine receptor D2 agonist effect. It is a partial agonist at dopamine D2 receptors designed to have a similar binding affinity to dopamine and serotonin receptors. The efficacy of brexpiprazole may be mediated through a combination of partial agonist activity at serotonin 5-HT1A and dopamine D2 receptors, and antagonist activity at serotonin 5-HT2A receptors. Brexpiprazole exhibits high affinity (subnanomolar) for these receptors as well as for noradrenaline alpha1B/2C receptors.

Bipolar Disorder Market Outlook

At present, some companies have initiated clinical trials that investigate new treatment options. Key players such as Intra-Cellular Therapies (Caplyta, also known as Lumateperone), NeuroRx (NRX-100/NRX-101), Sunovion (Sumitomo Dainippon Pharma) (SEP-4199), Lundbeck/Otsuka Pharmaceutical (Rexulti/Rxulti, also known as Brexpiprazole), COMPASS Pathways (COMP 360, also known as Psilocybin therapy), Celon Pharma (Falkieri), and several others are investigating their candidates for the management of Bipolar Disorder (Manic Depression) in the 7MM.

Key Findings

The Bipolar Disorder (Manic Depression) market size in the 7MM is expected to change during the study period 2017–2030. The therapeutic market of Bipolar Disorder (Manic Depression) in the seven major markets is expected to increase during the study period (2017–2030) with a CAGR of 11.9%. According to the estimates, the highest market size of Bipolar Disorder (Manic Depression) is found in the United States followed by Germany.

The United States Market Outlook

The total market size of Bipolar Disorder (Manic Depression) therapies in the United States is expected to increase with a CAGR of 11.6% in the study period (2017–2030).

 

EU-5 Countries: Market Outlook

The total market size of Bipolar Disorder (Manic Depression) therapies in EU-5 countries is expected to increase with a CAGR of 13.4% in the study period (2017–2030).

 

Japan Market Outlook

The total market size of Bipolar Disorder (Manic Depression) therapies in Japan is expected to increase with a CAGR of 11.5% in the study period (2017–2030).

Request for sample pages @ Bipolar Disorder Market

Table of contents

1. Key Insights

2. Report Introduction

3. Bipolar Disorder (Manic Depression) Market Overview at a Glance

3.1. Market Share (%) Distribution of Bipolar Disorder (Manic Depression) in 2017

3.2. Market Share (%) Distribution of Bipolar Disorder (Manic Depression) in 2030

4. Executive Summary of Bipolar Disorder (Manic Depression)

5. Epidemiology and Market Methodology

6. Disease Background and Overview

6.1. Introduction

6.2. Difference between Bipolar and Unipolar Depression

6.3. Classification of BD According to DSM-5

6.4. Signs and symptoms

6.5. Causes

6.6. Risk Factors

6.7. Pathophysiology

6.8. Genetic Findings in BD

6.9. Biomarkers

7. Diagnosis of Bipolar Disorder

7.1. Diagnostic criteria for major forms of BD

7.1.1. Diagnosis to rule out thyroid disorders

7.2. Differential Diagnosis

7.3. Diagnostic Guidelines

7.3.1. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology Guidelines

7.3.2. The National Institute for Health and Care Excellence (NICE) guidelines for the diagnosis of the bipolar disorder

8. Current Treatment Practices of Bipolar Disorder

8.1. Treatment of Bipolar Disorder

8.1.1. Treatment Algorithm

8.2. Treatment Guidelines

8.2.1. The World Federation of Societies of Biological Psychiatry (WFSBP) Guidelines for the Biological Treatment of Bipolar Disorders: Update 2010 on the treatment of acute Bipolar Disorder (Manic Depression)

8.2.2. The World Federation of Societies of Biological Psychiatry (WFSBP) guidelines for the biological treatment of bipolar disorders: update 2012 on the long-term treatment of the bipolar disorder

8.2.3. The American Psychiatric Association Practice Guideline for the Treatment of Bipolar Disorder

8.2.4. The National Institute for Health and Care Excellence (NICE) guidelines for the treatment of the bipolar disorder

8.2.5. Evidence-based guidelines for treating bipolar disorder: Revised third edition recommendations from the British Association for Psychopharmacology

8.2.6. Guideline for the treatment of bipolar disorder by the Japanese Society of Mood Disorders, 2012

8.2.7. International Society for Bipolar Disorders Clinical (ISBD) Recommendations for Antidepressant Use in Bipolar Disorders

8.2.8. The International College of Neuro-psychopharmacology (CINP) Treatment Guidelines for Bipolar Disorder in Adults (CINP-BD-2017)

8.3. Comparison of Bipolar disorder guidelines

9. Epidemiology and Patient Population

9.1. Key Findings

9.2. Epidemiology of Bipolar Disorder (Manic Depression)

9.3. Epidemiology Scenario: 7MM

9.3.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

9.3.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

9.3.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

9.3.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

10. The United States

10.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

10.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

10.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

10.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11. EU-5

11.1. Germany

11.1.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.1.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.1.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.1.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.2. France

11.2.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.2.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.2.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.2.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.3. Italy

11.3.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.3.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.3.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.3.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.4. Spain

11.4.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.4.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.4.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.4.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

11.5. The United Kingdom

11.5.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.5.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.5.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

11.5.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

12. Japan

12.1. Total Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

12.2. Type-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

12.3. Severity-specific Diagnosed Prevalent Cases of Bipolar Disorder (Manic Depression)

12.4. Total Treated Cases of Bipolar Disorder (Manic Depression)

13. Patient Journey

14. Key Endpoints in Bipolar Disorder (Manic Depression) Clinical Trials

15. Marketed Therapies

15.1. Vraylar (Cariprazine): Allergan (AbbVie)/Gedeon Richter

15.1.1. Drug Description

15.1.2. Regulatory Milestones

15.1.3. Other Developmental Activities

15.1.4. Pivotal Clinical Trial

15.1.5. Ongoing Current Pipeline Activity

15.2. Latuda (Lurasidone Hydrochloride): Sunovion Pharmaceuticals (Sumitomo Dainippon Pharma)

15.2.1. Drug Description

15.2.2. Regulatory Milestones

15.2.3. Other Developmental Activities

15.2.4. Pivotal Clinical Trial

16. Emerging Therapies

16.1. Caplyta (ITI-007; Lumateperone): Intra-Cellular Therapies

16.1.1. Product Description

16.1.2. Other Developmental Activities

16.1.3. Clinical Development

16.1.4. Safety and Efficacy

16.2. NRX-100/NRX-101: NeuroRx

16.2.1. Product Description

16.2.2. Other Developmental Activities

16.2.3. Clinical Development

16.2.4. Safety and Efficacy

16.3. SEP-4199: Sunovion (Sumitomo Dainippon Pharma)

16.3.1. Product Description

16.3.2. Other Developmental Activities

16.3.3. Clinical Development

16.3.4. Safety and Efficacy

16.4. Rexulti/Rxulti (Brexpiprazole): Lundbeck/Otsuka Pharmaceutical

16.4.1. Product Description

16.4.2. Other Developmental Activities

16.4.3. Clinical Development

16.4.4. Safety and Efficacy

16.5. Falkieri (Esketamine): Celon Pharma

16.5.1. Product Description

16.5.2. Other Developmental Activities

16.5.3. Clinical Development

16.5.4. Safety and Efficacy

16.6. COMP 360 (Psilocybin): COMPASS Pathways

16.6.1. Product Description

16.6.2. Other Developmental Activities

16.6.3. Clinical Development

17. Bipolar Disorder (Manic Depression): 7 Major Market Analysis

17.1. Key Findings

17.2. Market Outlook

17.3. 7MM Market Size

17.3.1. Total Market Size of Bipolar Disorder (Manic Depression) in the 7MM

17.3.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in the 7MM

18. The United States Market Size

18.1. Total Market Size of Bipolar Disorder (Manic Depression) in the United States

18.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in the United States

19. EU-5 Market Size

19.1. Germany

19.1.1. Total Market size of Bipolar Disorder (Manic Depression) in Germany

19.1.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Germany

19.2. France

19.2.1. Total Market size of Bipolar Disorder (Manic Depression) in France

19.2.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in France

19.3. Italy

19.3.1. Total Market size of Bipolar Disorder (Manic Depression) in Italy

19.3.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Italy

19.4. Spain

19.4.1. Total Market size of Bipolar Disorder (Manic Depression) in Spain

19.4.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Spain

19.5. The United Kingdom

19.5.1. Total Market size of Bipolar Disorder (Manic Depression) in the United Kingdom

19.5.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in the United Kingdom

20. Japan

20.1. Total Market size of Bipolar Disorder (Manic Depression) in Japan

20.2. Market Size of Bipolar Disorder (Manic Depression) by Therapies in Japan

21. Market Access and Reimbursement

21.1. Key HTA decisions for Bipolar Disorder (Manic Depression)

21.2. Patient Access Programs

22. Market Drivers

23. Market Barriers

24. SWOT Analysis

25. Unmet Needs

26. Appendix

26.1. Bibliography

26.2. Report Methodology

27. DelveInsight Capabilities

28. Disclaimer

29. About DelveInsight

Categories
All News

PALMAR HYPERHIDROSIS MARKET, EPIDEMIOLOGY AND MARKET FORECAST – 2030

DelveInsight’s ‘Palmar Hyperhidrosis Market Insights, Epidemiology, and Market Forecast – 2030’ report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends of Palmar Hyperhidrosis in the United States. 

Palmar Hyperhidrosis Market

The Palmar Hyperhidrosis market report provides analysis regarding current treatment practices, an emerging drug, like Dexmecamylamine (Atacama Therapeutics), Qbrexza (Dermira Inc), potential therapies, market share of the individual therapies, historical, current, and forecasted Palmar Hyperhidrosis market size from 2017 to 2030 for the United States.

The report also covers current Palmar Hyperhidrosis treatment practice/algorithm, market drivers, market barriers, and unmet medical needs to curate the best of the opportunities and assess the underlying potential of the market.

Geography Covered

  • The United States

Palmar Hyperhidrosis Overview

Palmar hyperhidrosis (PH) is a relatively common condition characterized by excessive hand sweating beyond normal thermoregulatory needs.

 

Palmar Hyperhidrosis Epidemiology

The Palmar Hyperhidrosis epidemiology chapters provide insights about historical and current Palmar Hyperhidrosis patient pool and forecasted trends for US. It helps recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. Palmar Hyperhidrosis Palmar Hyperhidrosis epidemiology is segmented by Diagnosed Prevalent Cases of Palmar Hyperhidrosis, Diagnosed cases of Palmar Hyperhidrosis, cases of Palmar Hyperhidrosis by Age, and Severe cases of Palmar Hyperhidrosis. The report includes a thorough analysis of all segmentations.

In the US, the cases of Hyperhidrosis were 15,634,521 in 2017. Moreover, the total diagnosed prevalent cases of Palmar Hyperhidrosis in the United States were found to be 1,407,107 in 2017.

According to DelveInsight’s analysis, In the United States, the highest number of Palmar Hyperhidrosis was reported to be among individuals above 18 years of age.

In the United States, out of all the total prevalent cases reported 773,909 severe and 633,198 non-severe cases for Palmar Hyperhidrosis in 2017.

Palmar Hyperhidrosis Drug Chapters

The drug chapter segment of the Palmar Hyperhidrosis report encloses the detailed analysis of the Palmar Hyperhidrosis pipeline drug. It also helps understand the Palmar Hyperhidrosis clinical trial details, expressive pharmacological action, agreements of the included drug, and the latest news and press releases.

Treatment is focused entirely on managing symptoms and supporting the health and well-being of the affected child or adult. The management of Palmar Hyperhidrosis revolves around the appropriate therapies for the physical and neurological problems encountered in the condition and provision for the special educational needs, given the precise cognitive profiles and behavioral features of the condition. There are many upcoming mono and combinational therapies such as Dexmecamylamine (Atacama Therapeutics), Qbrexza (Dermira Inc), etc. for the treatment of Palmar Hyperhidrosis in the pipeline.

Palmar Hyperhidrosis Market Outlook

The Palmar Hyperhidrosis market size is expected to increase at a significant CAGR during the study period (2017–2030). The United States accounts for the Palmar Hyperhidrosis market size, with USD 246.1 million in 2017.

Report Highlights

  • In the coming years, the Palmar Hyperhidrosis market scenario is expected to alter across the USA due to the launch of novel therapies with new mechanisms of action considering the high unmet medical need
  • Our in-depth analysis of the pipeline assets across different stages of development (Phase II), different emerging trends, and comparative analysis of pipeline products with detailed clinical profiles, launch date along with product development activities will support the clients in the decision-making process regarding their therapeutic portfolio by identifying the overall scenario of the research and development activities.

Table of contents

1. Key Insights

2. Executive Summary of Palmar Hyperhidrosis

3. Competitive Intelligence Analysis for Palmar Hyperhidrosis

4. Palmar Hyperhidrosis: Market Overview at a Glance

4.1. Palmar Hyperhidrosis Total Market Share (%) Distribution in 2017

4.2. Palmar Hyperhidrosis Total Market Share (%) Distribution in 2030

5. Palmar Hyperhidrosis: Disease Background and Overview

5.1. Introduction

5.2. Sign and Symptoms

5.3. Pathophysiology

5.4. Risk Factors

5.5. Diagnosis

6. Patient Journey

7. Palmar Hyperhidrosis Epidemiology and Patient Population

7.1. Epidemiology Key Findings

7.2. Assumptions and Rationale: 7MM

7.3. Epidemiology Scenario: 7MM

7.3.1. Palmar Hyperhidrosis Epidemiology Scenario in the 7MM (2017-2030)

7.4. United States Epidemiology

7.4.1. Palmar Hyperhidrosis Epidemiology Scenario in the United States (2017-2030)

7.5. EU-5 Country-wise Epidemiology

7.5.1. Germany Epidemiology

7.5.1.1. Palmar Hyperhidrosis Epidemiology Scenario in Germany (2017-2030)

7.5.2. France Epidemiology

7.5.2.1. Palmar Hyperhidrosis Epidemiology Scenario in France (2017-2030)

7.5.3. Italy Epidemiology

7.5.3.1. Palmar Hyperhidrosis Epidemiology Scenario in Italy (2017-2030)

7.5.4. Spain Epidemiology

7.5.4.1. Palmar Hyperhidrosis Epidemiology Scenario in Spain (2017-2030)

7.5.5. United Kingdom Epidemiology

7.5.5.1. Palmar Hyperhidrosis Epidemiology Scenario in the United Kingdom (2017-2030)

7.5.6. Japan Epidemiology

7.5.6.1. Palmar Hyperhidrosis Epidemiology Scenario in Japan (2017-2030)

8. Treatment Algorithm, Current Treatment, and Medical Practices

8.1. Palmar Hyperhidrosis Treatment and Management

8.2. Palmar Hyperhidrosis Treatment Algorithm

9. Unmet Needs

10. Key Endpoints of Palmar Hyperhidrosis Treatment

11. Marketed Products

11.1. List of Marketed Products in the 7MM

11.2. Drug Name: Company Name

11.2.1. Product Description

11.2.2. Regulatory Milestones

11.2.3. Other Developmental Activities

11.2.4. Pivotal Clinical Trials

11.2.5. Summary of Pivotal Clinical Trial

List to be continued in report

12. Emerging Therapies

12.1. Key Cross

12.2. Drug Name: Company Name

12.2.1. Product Description

12.2.2. Other Developmental Activities

12.2.3. Clinical Development

12.2.4. Safety and Efficacy

12.2.5. Product Profile

List to be continued in report

13. Palmar Hyperhidrosis: Seven Major Market Analysis

13.1. Key Findings

13.2. Palmar Hyperhidrosis Market Size in 7MM

13.3. Palmar Hyperhidrosis Market Size by Therapies in the 7MM

14. Attribute analysis

15. 7MM: Market Outlook

15.1. United States: Market Size

15.1.1. Palmar Hyperhidrosis Total Market Size in the United States

15.1.2. Palmar Hyperhidrosis Market Size by Therapies in the United States

15.2. EU-5 countries: Market Size and Outlook

15.3. Germany Market Size

15.3.1. Palmar Hyperhidrosis Total Market Size in Germany

15.3.2. Palmar Hyperhidrosis Market Size by Therapies in Germany

15.4. France Market Size

15.4.1. Palmar Hyperhidrosis Total Market Size in France

15.4.2. Palmar Hyperhidrosis Market Size by Therapies in France

15.5. Italy Market Size

15.5.1. Palmar Hyperhidrosis Total Market Size in Italy

15.5.2. Palmar Hyperhidrosis Market Size by Therapies in Italy

15.6. Spain Market Size

15.6.1. Palmar Hyperhidrosis Total Market Size in Spain

15.6.2. Palmar Hyperhidrosis Market Size by Therapies in Spain

15.7. United Kingdom Market Size

15.7.1. Palmar Hyperhidrosis Total Market Size in the United Kingdom

15.7.2. Palmar Hyperhidrosis Market Size by Therapies in the United Kingdom

15.8. Japan Market Outlook

15.8.1. Japan Market Size

15.8.2. Palmar Hyperhidrosis Total Market Size in Japan

15.8.3. Palmar Hyperhidrosis Market Size by Therapies in Japan

16. Access and Reimbursement Overview of Palmar Hyperhidrosis

17. KOL Views

18. Market Drivers

19. Market Barriers

20. Appendix

20.1. Bibliography

20.2. Report Methodology

21. DelveInsight Capabilities

22. Disclaimer

23. About DelveInsight

Request for sample pages @ Palmar Hyperhidrosis Market Outlook